Repository logo
 

SARS-CoV-2 3D database: Understanding the Coronavirus Proteome and Evaluating Possible Drug Targets.

Accepted version
Peer-reviewed

Loading...
Thumbnail Image

Change log

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly growing infectious disease, widely spread with high mortality rates. Since the release of the SARS-CoV-2 genome sequence in March 2020, there has been an international focus on developing target-based drug discovery, which also requires knowledge of the 3D structure of the proteome. Where there are no experimentally solved structures, our group has created 3D models with coverage of 97.5% and characterised them using state-of-the-art computational approaches. Models of protomers and oligomers, together with predictions of substrate and allosteric binding sites, protein- ligand docking, SARS-CoV-2 protein interactions with human proteins, impacts of mutations, and mapped solved experimental structures are freely available for download. These are imple- mented in SARS CoV-2 3D, a comprehensive and user-friendly database, available at https://sars3d.com/. This provides essential information for drug discovery, both to evaluate targets and design new potential therapeutics.

Description

Journal Title

Briefings in Bioinformatics

Conference Name

Journal ISSN

1467-5463
1477-4054

Volume Title

22

Publisher

Oxford University Press (OUP)

Rights and licensing

Except where otherwised noted, this item's license is described as All rights reserved
Sponsorship
American Leprosy Missions (unknown)
Wellcome Trust (200814/Z/16/Z)
Biotechnology and Biological Sciences Research Council (BB/M011194/1)
This work is supported and funded by King Abdullah scholarship (Saudi Arabia research coun- cil), and American Leprosy Missions grants (G88726), SET is funded by the Cystic Fibrosis Trust (RG 70975) and Fondation Botnar (RG91317). A.R.J is funded by the Biotechnology and Biological Sciences Research Council (BBSRC) DTP studentship (BB/M011194/1). B.B. is funded by the Cystic Fibrosis Trust and L.C. on a studentship from Ipsen. T.L.B. is funded by a the Wellcome Trust Investigator Award, PHZJ/489 RG83114 (2016-2021)